A Phase 1 interventional study of Midazolam and Imlunestrant in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effect of imlunestrant (LY3484356) when administered orally on the levels of midazolam in the blood stream in healthy women of non-childbearing potential. The study will also evaluate the safety and tolerability of imlunestrant in healthy women of non-childbearing potential. This study will last up to approximately 6 weeks for each participant including the screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 400 milligram (mg) Imlunestrant (2 × 200 mg) tablets administered once daily (QD) orally for 7 days on Days 3 to 9 and a single dose of 0.5 mg midazolam solution orally on Day 1 and Day 9 as per below dosing sequence: Day 1: 0.5 mg midazolam alone Days 3 to 8: 400 mg imlunestrant QD alone Day 9: 0.5 mg midazolam + 400 mg imlunestrant There was a washout period of 8 days between doses of midazolam.
Drug: Midazolam · Drug: Imlunestrant
Administered orally.
Administered orally.
Also known as: LY3484356
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
PK: AUC\[0-∞\] of Midazolam
Time frame: Day 1: Predose, 0.25hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
PK: Maximum Observed Concentration (Cmax) of Midazolam
PK: Cmax of Midazolam
Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
PK: AUC[0-∞] of 1'-Hydroxymidazolam
PK: AUC\[0-∞\] of 1'-hydroxymidazolam
Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
PK: Cmax of 1'-Hydroxymidazolam
PK: Cmax of 1'-hydroxymidazolam
Time frame: Day 1: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose; Day 9: Predose, 0.25h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24, 36, 48h postdose
PK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam
PK: AUC\[0-24\], ss of Imlunestrant
Time frame: Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose
PK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam
PK: Cmax, ss of Imlunestrant when dosed in the presence of Midazolam is evaluated.
Time frame: Day 9: Predose, 0.25 h, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h and 24h postdose
| Milestone | Midazolam + Imlunestrant |
|---|---|
| Started | 20 |
| Received at least one dose of study drug | 20 |
| Completed | 19 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
PK: AUC\[0-∞\] of Midazolam
| nanogram*hour per milliliter (ng*hr/mL) | 0.5 mg Midazolam | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam | 12.3 ± 32 | 11.4 ± 41 |
PK: Cmax of Midazolam
| nanograms per milliliter (ng/mL) | 0.5 mg Midazolam | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Midazolam | 3.84 ± 35 | 4.12 ± 31 |
PK: AUC\[0-∞\] of 1'-hydroxymidazolam
| ng*hr/mL | 0.5 mg Midazolam | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|---|
| PK: AUC[0-∞] of 1'-Hydroxymidazolam | 2.75 ± 40 | 2.26 ± 40 |
PK: Cmax of 1'-hydroxymidazolam
| ng/mL | 0.5 mg Midazolam | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|---|
| PK: Cmax of 1'-Hydroxymidazolam | 0.748 ± 40 | 0.722 ± 35 |
PK: AUC\[0-24\], ss of Imlunestrant
| ng*hr/mL | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|
| PK: Area Under the Concentration Versus Time Curve From Zero to 24 Hours at Steady State (AUC[0-24], ss) of Imlunestrant When Dosed in the Presence of Midazolam | 2020 ± 53 |
PK: Cmax, ss of Imlunestrant when dosed in the presence of Midazolam is evaluated.
| ng/mL | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|
| PK: Maximum Observed Concentration at Steady State (Cmax, ss) of Imlunestrant When Dosed in the Presence of Midazolam | 120 ± 51 |
Collected over Baseline Up to Day 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5 mg Midazolam | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| 400 mg Imlunestrant | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| 0.5 mg Midazolam + 400 mg Imlunestrant | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Event | 0.5 mg Midazolam | 400 mg Imlunestrant | 0.5 mg Midazolam + 400 mg Imlunestrant |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/20 | 3/20 | 1/20 |
| HeadacheNervous system disorders | 0/20 | 2/20 | 0/20 |
All enrolled participants.
| Age, Continuous(years) | Midazolam + Imlunestrant |
|---|---|
| Mean | 50.8 ± 7.5 |
| Sex: Female, Male(Participants) | Midazolam + Imlunestrant |
|---|---|
| Female | 20 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Midazolam + Imlunestrant |
|---|---|
| Hispanic or Latino | 14 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Midazolam + Imlunestrant |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Midazolam + Imlunestrant |
|---|---|
| United States | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Nov 2022, 2 months.
Results were first posted in Nov 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imlunestrant